TESARO Competitors and Similar CompaniesClear all
TESARO's competitors and similar companies include BeyondSpring, Takeda, Cantex Pharmaceuticals and Oncoceutics.
 TESARO TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. |  BeyondSpring BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Cantex Pharmaceuticals Cantex Pharmaceuticals is a pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer. |  Oncoceutics Oncoceutics was a biotechnology company that developed small molecule compounds targeting G protein-coupled receptors for oncology applications. | |
Founding Date | Founding Date 2010 | Founding Date 2010 | Founding Date 1781 | Founding Date 2002 | Founding Date 2009 |
Type | Type Subsidiary | Type Public | Type Public | Type Private | Type Subsidiary |
Tags | |||||
Locations | Locations Florham Park, US HQ | Locations Weston, US HQ | Locations Philadelphia, US HQ | ||
Employees | Employees 446 | Employees 4014% increase | Employees 47,4554% decrease | Employees 650% increase | Employees 12 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 89.4 m | Valuation ($) 43.7 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $223.3m (FY, 2017) | Revenue (est.) N/A | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $41.1m (FY, 2017) | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $182.2m (FY, 2017) | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($496.1m) (FY, 2017) | Net income ($16.7m) (FY, 2024) | Net income ¥108.1b (FY, 2025) | Net income N/A | Net income N/A |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2019) | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 1 (FY, 2017) | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2019) | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 161m | Total funding raised $ 36.1m | Total funding raised $ 57.8m | Total funding raised $ 27.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
BeyondSpring
HQ
Florham Park, US
Employees
40↑ 14% increase
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company focused on oncology therapies.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyCantex Pharmaceuticals
HQ
Weston, US
Employees
6↑ 50% increase
Cantex Pharmaceuticals is a pharmaceutical company developing proprietary pharmaceuticals that improve the treatment of cancer.
View companyOncoceutics
HQ
Philadelphia, US
Oncoceutics was a biotechnology company that developed small molecule compounds targeting G protein-coupled receptors for oncology applications.
View company